Access to Outpatient Longitudinal Drug Utilization Data
ID: FDASSN126594Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA CENTER FOR DRUG EVALUATION AND RESEARCHSilver Spring, MD, 20993, USA

NAICS

Other Computer Related Services (541519)

PSC

SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA (B529)

Original Source

https://sam.gov/opp/2bd1721ab38f4f4faa7aad70828b2200/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking information from small businesses regarding their capabilities to provide access to outpatient longitudinal drug utilization data. The objective of this procurement is to identify qualified small business sources that can supply existing, HIPAA-compliant data resources to enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions. This initiative is crucial for improving public health through better data access and analysis capabilities, with a projected contract duration of five years. Interested firms must submit their responses by 10 AM on January 23, 2025, to Telisha Wilson at telisha.wilson@fda.hhs.gov, including their business size status and DUNS number.

    Point(s) of Contact
    Telisha Wilson
    telisha.wilson@fda.hhs.gov
    Files
    Title
    Posted
    Source Sought.pdf
    The U.S. Food and Drug Administration (FDA) released a Sources Sought notice (FDA-SSN-126594) on December 23, 2024, seeking information from small businesses regarding their capabilities to provide access to outpatient longitudinal drug utilization data. This notice aims to identify qualified small business sources, including various classifications such as HUBZone, veteran-owned, and woman-owned businesses, under NAICS code 541519. The FDA underscores the significance of acquiring access to real-time, comprehensive data on outpatient prescriptions and patient demographics to enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions. The agency emphasizes the necessity of existing, HIPAA-compliant data resources rather than developing new databases. Interested firms must submit responses by January 23, 2025, and provide their business size status and DUNS number. The contract is projected to span five years, and the notice highlights that no obligation for contract award is assumed by the government. Ultimately, this initiative reinforces the FDA's commitment to ensuring public health through improved data access and analysis capabilities.
    Lifecycle
    Title
    Type
    Access to Outpatient Longitudinal Drug Utilization Data
    Currently viewing
    Sources Sought
    Similar Opportunities
    Safe Medication Use
    Active
    Health And Human Services, Department Of
    The U.S. Food and Drug Administration (FDA) is conducting a Request for Information (RFI) to identify potential sources capable of providing medication error reports, an analytics platform, and related services aimed at preventing and analyzing medication errors. This initiative, led by the FDA's Center for Drug Evaluation and Research, seeks organizations that can supply nationwide data from healthcare providers, consumers, and patient safety organizations, emphasizing the importance of robust reporting, data analysis, and training in enhancing medication safety protocols. Interested parties, particularly small businesses, are encouraged to submit their capability statements by January 6th, 2025, and should note that responses are voluntary and do not imply a commitment for a contract. For further inquiries, contact Brian Wodzisz at Brian.Wodzisz@fda.hhs.gov or call 301-796-7376.
    FDA Regulated Products Sampling Services
    Active
    Health And Human Services, Department Of
    The U.S. Food and Drug Administration (FDA) is seeking qualified vendors to provide Sampling Services for FDA-regulated products through a Sources Sought Notice (Ref No. 75F40125R00032). The primary objective of this procurement is to identify capable businesses that can collect physical samples of food, drugs, medical devices, and other products for laboratory analysis, ensuring safety and verifying labeling accuracy. This initiative is crucial for the FDA's regulatory oversight, as it supports the monitoring of product safety and quality, which may include both domestic and imported goods. Interested parties must submit their responses by January 9, 2025, and can contact Amanda Lusk at Amanda.Lusk@fda.hhs.gov or Nicholas Bisher at Nicholas.Bisher@fda.hhs.gov for further information.
    FY25 Docker Enterprise Edition Licenses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for the procurement of Docker Enterprise Edition licenses to support the development of its Containers as a Service (CaaS) platform. The objective of this contract is to enhance the FDA's IT infrastructure by utilizing Docker EE’s container technology, which is essential for improving operational efficiency and reducing costs compared to traditional virtual machines. This procurement is significant as it enables the FDA to deploy applications in various environments while ensuring compliance with federal security mandates. Interested small businesses must submit their quotes by January 2, 2025, and can direct inquiries to Terina Hicks at terina.hicks@fda.hhs.gov or Roosevelt Walker at roosevelt.walker@fda.hhs.gov.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    PRIMO Software Licensing
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
    MRC Biosafety Cabinet Evaluation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking qualified small businesses to provide engineering evaluation services for biological safety cabinets (BSCs) at its Center for Veterinary Medicine. The primary objective of this procurement is to assess existing BSCs that are failing to meet certification standards, particularly focusing on their associated HVAC and control systems, and to provide recommendations for replacements. This evaluation is crucial for maintaining laboratory safety and operational efficiency, ensuring compliance with federal safety standards. Interested parties must attend a mandatory site visit on December 17, 2024, and submit their quotations by January 8, 2025, to the contracting officer, Sheneil Green, at Sheneil.Green@fda.hhs.gov.
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The RFI aims to gather details on vendors' capabilities to supply FDA-approved pharmaceuticals, including Amoxicillin, Ciprofloxacin, and Clindamycin, which are critical for public health emergencies. This procurement is vital for ensuring rapid access to life-saving medical supplies during biological, chemical, and radiological threats, as well as natural disasters. Interested vendors must submit their responses electronically by January 8, 2025, and can direct inquiries to Terri Reed at terri.reed@hhs.gov.
    FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Bruker Maldi TOF Maintenance
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking proposals for a full-service maintenance agreement for its Bruker MALDI TOF system, with a contract start date of January 16, 2025, and four optional one-year extensions. The contractor will be responsible for comprehensive maintenance services, including all repairs, annual preventative maintenance, and ensuring compliance with regulatory standards, with a focus on supporting the FDA's mission to monitor antimicrobial resistance in foodborne and zoonotic pathogens. Interested small businesses must submit their quotes by 11:59 PM EST on January 3, 2025, and can direct inquiries to James O’Keefe at 301-796-7371 or via email at James.OKeefeIII@fda.hhs.gov.
    Solicitation: Tobacco Retailer Inspections - 75F40125R00018
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is soliciting proposals for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to conduct tobacco retailer inspections across multiple regions in the United States. The primary objective of this procurement is to ensure compliance with federal laws regarding the sale and advertising of tobacco products, particularly focusing on preventing youth access to these products. This initiative is critical for enhancing the FDA's enforcement capabilities and protecting public health by reducing tobacco use among minors. Interested contractors should contact Janice Heard at janice.heard@fda.hhs.gov or Brandon Rafus at brandon.rafus@fda.hhs.gov for further details, with the contract period spanning five years and specific funding amounts to be determined for each region.